Guggenheim Capital’s Collegium Pharmaceutical COLL Stock Holding History

Guggenheim Capital’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$783K	Buy	21,637 +15,541	+255%	+$531K	﹤0.01%	1112
2026 Q1	$202K	Sell	6,096 -25,566	-81%	-$1.08M	﹤0.01%	1523
2025 Q4	$1.47M	Buy	+31,662	New	+$1.32M	0.01%	772
2024 Q3	–	Sell	-32,038	Closed	-$1.03M	–	1879
2024 Q2	$1.03M	Buy	32,038 +17,525	+121%	+$608K	0.01%	1101
2024 Q1	$563K	Buy	+14,513	New	+$508K	﹤0.01%	1429
2022 Q3	–	Sell	-39,309	Closed	-$697K	–	1934
2022 Q2	$697K	Buy	39,309 +2,116	+6%	+$35.6K	0.01%	1407
2022 Q1	$757K	Sell	37,193 -465	-1%	-$8.79K	﹤0.01%	1498
2021 Q4	$703K	Sell	37,658 -4,068	-10%	-$79.3K	﹤0.01%	1518
2021 Q3	$823K	Sell	41,726 -7,797	-16%	-$169K	﹤0.01%	1520
2021 Q2	$1.17M	Sell	49,523 -1,926	-4%	-$44.5K	0.01%	1402
2021 Q1	$1.22M	Buy	51,449 +19,879	+63%	+$472K	0.01%	1295
2020 Q4	$632K	Buy	31,570 +11,392	+56%	+$222K	﹤0.01%	1538
2020 Q3	$420K	Buy	+20,178	New	+$364K	﹤0.01%	1505

Other funds holding COLL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Guggenheim Capital's COLL Position: Q2 2026 in Review

Guggenheim Capital increased its Collegium Pharmaceutical (COLL) stake by 255% in Q2 2026, buying an estimated $531K and bringing the position to 21,637 shares worth $783K. The position accounts for ﹤0.01% of the portfolio, ranked #1112.

Guggenheim Capital first reported a position in COLL in Q3 2020 and has held it in 13 quarters since. The position peaked at $1.47M in Q4 2025. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

Guggenheim Capital held 21,637 shares of Collegium Pharmaceutical worth $783K as of Q2 2026.
Guggenheim Capital bought 15,541 Collegium Pharmaceutical shares in Q2 2026, an estimated $531K.
Collegium Pharmaceutical made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1112 holding.
Guggenheim Capital first reported a position in Collegium Pharmaceutical in Q3 2020 and has held it in 13 quarters since.
Guggenheim Capital's Collegium Pharmaceutical position peaked at $1.47M in Q4 2025.
279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.